REC-4881 not checked
Recursion Pharmaceuticals Inc.
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Familial Adenomatous Polyposis
- Main trialPhase 1/2
- “This is a multicenter, two-part trial in participants with FAP.”In the company’s words, NCT05552755 on ClinicalTrials.gov
Other drugs for Familial Adenomatous Polyposis
Coming up1
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jun 2027 | Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | |
| Phase 2Terminated | 24 Feb 2025 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026